Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Hokkaido Univ., PuREC, Mochida Launch Joint Research on Novel Treatment for Spine-Related Diseases
February 3, 2021
- Nichi-Iko Closes Acquisition of Teva Takeda’s Generic Biz
February 2, 2021
- Ono Logs 4.3% Sales Growth in April-December, Opdivo Jumps
February 2, 2021
- Astellas Returns Rights to Prostate Cancer Med to US Firm
February 2, 2021
- Sumitomo Dainippon to Invest Up to US$20 Million in US Venture Fund Focused on Digital Health
February 2, 2021
- Shuhei Sekiguchi to Become Janssen Japan Chief on March 1
February 2, 2021
- Sosei Ties Up with UK CRO to Identify Lead Compounds in Neurological Diseases
February 2, 2021
- Shionogi Sees Double-Digit Sales Decline in April-December as Infectious Disease Meds Suffer
February 2, 2021
- Astellas Sees Growth of Evrenzo after 14-Day Prescription Limit Lifted: EVP
February 1, 2021
- FunPep Initiates Development of New IL-23 Antibody-Inducing Peptide
February 1, 2021
- Teijin to Acquire Fujifilm's J-TEC for Up to 21.6 Billion Yen
February 1, 2021
- Asahi Kasei Pharma Licenses Chronic Pain Drug AK1780 to Eli Lilly
February 1, 2021
- Daiichi Sankyo’s Revenue Down 2.4% in April-December as Mainstays Flounder at Home
February 1, 2021
- Astellas’ 9-Month Earnings Stumble on Celecox Generic Erosion, Sales Pact Terminations
February 1, 2021
- FDA Delays Decision for Biogen’s Aducanumab to June 7
February 1, 2021
- Sumitomo Dainippon Logs Double-Digit Growth on Diabetes Meds: April-December
January 29, 2021
- Fujifilm Toyama Chemical Files Radiopharmaceutical F-1614
January 29, 2021
- Pfizer Japan Files Somatrogon for Growth Hormone Deficiency
January 29, 2021
- Relumina Submitted for Endometriosis Use in Japan: ASKA
January 29, 2021
- Ono Seeks Pediatric Nod for Opdivo in Hodgkin’s Lymphoma
January 29, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…